These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37937043)

  • 1. Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.
    Moenster RP; Wallace-Lacey A; Western H; Tiefenaur S; Abdulbasir A; Alberts J; Doty J; Abner H; Skouby D; Lorenz M; Fong R; Arora J; Linneman TW
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad411. PubMed ID: 37937043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
    Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
    BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
    Hamad Y; Nickel KB; Olsen MA; George IA
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible
    Hamad Y; Connor L; Bailey TC; George IA
    Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
    Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW
    Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
    Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
    Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
    Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
    J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant
    Zasowski EJ; Trinh TD; Claeys KC; Lagnf AM; Bhatia S; Klinker KP; Veve MP; Estrada SJ; Johns ST; Sawyer AJ; Huang V; LaFrance B; Levine DP; Kaye KS; Davis SL; Rybak MJ
    Open Forum Infect Dis; 2022 Mar; 9(3):ofab606. PubMed ID: 35146040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible
    Beganovic M; Cusumano JA; Lopes V; LaPlante KL; Caffrey AR
    Open Forum Infect Dis; 2019 Jul; 6(7):ofz270. PubMed ID: 31281864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
    Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
    Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
    Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
    Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
    Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftriaxone as an Alternative Therapy for the Treatment of Methicillin-Susceptible
    Barber KE; Cramer RA; Bell AM; Wagner JL; Stover KR
    Case Rep Infect Dis; 2021; 2021():8884685. PubMed ID: 33986964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
    McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
    Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.